Resources
About Us
Home Report
Store
Tissue Diagnostics Market
Tissue Diagnostics Market by Product Type (Antibodies, Kits, Reagents, Instruments [Slide Stainer, Scanner]), Technology (Digital Pathology, IHC, ISH, H&E Staining), Cancer Type (Breast, NSCLC, Colorectal, Prostate), and End user - Global Forecast to 2029
Report ID:MRHC - 104268 Pages: 226 Nov-2022 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe Tissue Diagnostics Market is projected to reach $8.52 billion by 2029, at a CAGR of 7.4% from 2022 to 2029. Biopsy, a procedure for detecting cancer, is recommended when an initial diagnostics test suggests an abnormality in an area of tissue in the body. It involves removing a small amount of abnormal tissue, which is sent to a laboratory for examination under a microscope. This process is called tissue diagnosis. Tissue diagnostics involves the study of tissue to diagnose disease and determine whether the tissue is cancerous, its type, and the characteristics of observed cancer. Tissue diagnostics uses instruments such as slide staining systems, slide scanners, tissue processing systems, embedding systems, and microarray.
The tissue diagnostics market is growing due to the rising prevalence of cancer globally, the availability of biomarkers and research on biomarkers, recommendations for cancer screening, the growing number of clinical trials for oncology drugs, and the availability of tissue-based companion diagnostics. Furthermore, the rising focus on personalized healthcare and the advent of digital pathology and tissue diagnosis automation offer significant market growth opportunities.
COVID-19 Impact Assessment
The COVID-19 pandemic negatively impacted the tissue diagnostics market due to the decrease in the number of people getting screened for cancer during the pandemic. In the U.S., screenings for cancers of the breast, colon, and cervix dropped by 94%, 86%, and 94% between 20th January 2020 and 21st April 2020, respectively (Source: Epic Research Journal). Many screening facilities closed temporarily, while others faced severe staffing shortages. Similarly, in Europe, cancer services were disrupted by 50% by the end of 2021 (Source: Global Pulse Survey). People were afraid to go to hospitals and other medical facilities for non-emergency procedures due to the fear of COVID-19, which negatively affected cancer screening practices.
In 2020, during the first lockdown, national screening programs for many cancers, such as colorectal carcinoma, breast carcinoma and cervical carcinoma, were paused in many countries. For instance,
- In May 2020, the Government of India suspended the population-based screening as part of the national program based on the risk associated with oral cavity examination. The Government launched the country’s first national cancer screening program in 2016 under the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS).
- In March 2020, the Scottish Government temporarily suspended the national screening programs for cervical, breast, and bowel cancers.
Thus, there was a decline in the screening rate, which affected the tissue diagnostics market. Apart from this, there were temporary supply chain disruptions due to lockdowns and travel restrictions, which also negatively affected the tissue diagnostics market.
Click here to: Get Free Sample Copy of this report
The Rising prevalence of Cancer Globally is Driving the Market Growth
According to World Health Organization (WHO), cancer is a leading cause of death worldwide, which accounted for 10 million deaths globally in 2020. Nearly 70% of cancer deaths occur in low and middle-income countries. Its early detection is important in reducing mortality, improving the chances of survival, and saving on treatment costs. The burden of cancer is growing globally, exerting tremendous economic strain on the countries. According to GLOBOCAN 2020, the number of new cancer cases is projected to reach 24.6 million in 2030 from 19.3 million in 2020. The International Agency for Research on Cancer (IARC) estimates that globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. Factors such as geriatric populations and socio-economic risks are driving this increase.
The Advent of Digital Pathology and Automation in Tissue Diagnostics is the Trend Prevailing in the Market
Automated tissue diagnostics are gaining acceptance due to the improved technical performance of the assays, which reduces reagent costs and assay time. Management of huge data and the lack of availability of skilled pathologists also contribute to the need for automation in tissue diagnostic systems. Innovations in the automation of staining equipment and novel platforms such as digital immunohistochemistry (IHC) are among the developments in tissue diagnostics.
Additionally, advanced laboratory information system (LIS) is also emerging in the field of tissue diagnostics. In the tissue diagnostics market, the development of end-to-end integrated workflow solutions will lead to the expansion of the market in the future. This can be achieved by collaborating with anatomic pathology LIS (APLIS) vendors and partnering with instrument distributors in emerging countries.
Automating the process is necessary as most of the workflow in a histology laboratory is manual. Many diagnostic equipment manufacturers are launching automated platforms to improve laboratory efficiency, reduce time, and provide pathologists with advanced systems for diagnosis. A few examples are mentioned below:
- In May 2022, Leica Biosystems (Germany) launched its BOND-PRIME, an advanced staining solution to expand diagnostic productivity in laboratories. This system enables lab technicians to load any slides in any combination, with any reagent, at any time.
- In August 2021, Lumito AB (Sweden) launched its instrument and staining reagents based on up-converting nanoparticles (UCNPs) used in tissue diagnostics. This provides visual depictions of tissue samples as input for making a diagnosis to the pathologists. The technology has several application areas, but the company initially focused on tissue diagnostics and digital pathology.
Key Findings in the Global Tissue Diagnostics Market Study:
Based on product type, in 2022, the consumables segment is expected to account for the largest share
Diagnostic consumables are one-time or limited-use items used during diagnosis. The large market share of this segment is attributed to the recurring requirement for consumables and research in developing novel reagents and other consumables. For example, the U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), a collaborative consortium of academic and private-sector investigators, focuses on the systematic discovery, development, and validation of biomarkers and imaging methods to detect early-stage cancers and to assess the risk associated to developing cancer. Such research studies are driving the demand for consumables for tissue diagnostics.
Based on technique, in 2022, the immunohistochemistry (IHC) segment is expected to account for the largest share
Immunohistochemistry provides variations between different types of tumors, which is why it is preferred over conventional enzyme staining techniques, especially in cancer screenings. Thus, the high adoption of cancer screening, technological developments in immunohistochemistry, and availability of reimbursement policies for IHC-based tests contribute to the large market share of this segment.
Based on application, in 2022, the breast cancer segment is expected to account for the largest share
The prevalence of breast cancer is high and rising gradually across the globe. According to WHO, in 2020, 2.3 million women were globally diagnosed with breast cancer. Thus, the high prevalence of breast cancer and the presence of funding programs to support research and early screening of breast cancer are the factors contributing to the large market share of this segment. For instance, in October 2021, The Breast Cancer Research Foundation (BCRF) announced a USD 47.5 million commitment to fund breast cancer research from 2021–2022.
Based on end user, in 2022, the hospitals & diagnostic laboratories segment is expected to account for the largest share
The high flow of patient pool to the hospitals & diagnostic laboratories due to the rising prevalence of cancer globally and an increase in the budget for adopting advanced technologies contribute to the large market share of this segment.
Asia-Pacific: Lucratively Growing Regional Market
The growth of this regional market is attributed to the growing cancer prevalence, improving healthcare services, rising healthcare spending, and early cancer screening in Asia-Pacific.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments the key market players adopted over the past three years. The key players profiled in the global tissue diagnostics market report are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (U.S.), Abcam plc (U.K.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Cell Signaling Technology, Inc. (U.S.), Bio-Genex Laboratories (U.S.), Bio SB, INC (U.S.), 3DHISTECH (Hungary), and HOLOGIC, INC. (U.S.)
Scope of the Report:
Tissue Diagnostics Market, by Product Type
- Consumables
- Kits & Reagents
- Antibodies
- Instruments
- Slide Staining Systems
- Slide Scanners
- Tissue Processors
- Tissue Microarrays
- Other Instruments
Note: Other instruments majorly include embedding systems, PCR, and NGS
Tissue Diagnostics Market, by Technique
- Immunohistochemistry (IHC)
- In-situ Hybridization (ISH)
- Digital Pathology
- H&E and Special Staining
- Molecular Diagnostics
- Other Techniques
Note: Other techniques majorly include flow cytometry, image cytometry, electron microscopy, and ELISA
Tissue Diagnostics Market, by Application
- Breast Cancer
- Lung Cancer
- Colorectal and Gastrointestinal Cancer
- Prostate Cancer
- Lymphoma
- Other Applications
Note: Other applications majorly include cervical cancer, skin cancer, and lip & oral cavity cancer
Tissue Diagnostics Market, by End User
- Hospitals & Diagnostic Laboratories
- Research Institutes
- Pharmaceutical Companies
- Contract Research Organizations
Tissue Diagnostics Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Key questions answered in the report:
This study offers a detailed assessment of the tissue diagnostics market, including the market size & forecast for various segmentations such as product type, technique, application, and end user. This report also involves the value analysis of various segments and sub-segments of the tissue diagnostics market at the regional and country levels.
The global tissue diagnostics market is projected to reach $8.52 billion by 2029, at a CAGR of 7.4% during the forecast period.
Based on product type, in 2022, the consumables segment is expected to account for the largest share of the market. Consumables such as antibodies, kits & reagents are extensively and recurringly used daily, thus attributing to the large market share of this segment.
Based on application, in 2022, the breast cancer segment is expected to account for the largest share of the market. The high prevalence of breast cancer and the presence of early breast cancer screening programs are the factors contributing to the large market share of this segment.
The growth of this market is attributed to the global rise in cancer prevalence and the increasing clinical trials for oncology drugs. Along with this, the rising focus on personalized healthcare, the advent of digital pathology, and the automation of tissue diagnosis are the major opportunities for existing market players and new entrants in the global tissue diagnostics market
The key players profiled in the global tissue diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (U.S.), Abcam plc (U.K.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Cell Signaling Technology, Inc. (U.S.), Bio-Genex Laboratories (U.S.), Bio SB, INC (U.S.), 3DHISTECH (Hungary), and HOLOGIC, INC. (U.S.).
Emerging economies in Asia-Pacific are projected to offer significant growth opportunities to the market players due to the growing cancer prevalence, the rising spending on healthcare, and the improving adoption of advanced technologies for cancer diagnostics.
- 1. Introduction
- 1.1. Market Definition
- 1.2. Market Ecosystem
- 1.3. Currency
- 1.4. Key Stakeholders
- 2. Research Methodology
- 2.1. Research Process
- 2.2. Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research
- 2.3. Market Assessment
- 2.3.1. Market Size Estimation
- 2.3.1.1. Bottom-up Approach
- 2.3.1.2. Top-down Approach
- 2.3.1.3. Growth Forecast
- 2.3.1. Market Size Estimation
- 2.4. Assumptions for the Study
- 2.5. Limitations for the Study
- 3. Executive Summary
- 4. Market Insights
- 4.1. Market Overview
- 4.2. Drivers
- 4.2.1. Rising Global Prevalence of Cancer
- 4.2.2. Availability of Biomarkers & Biomarker Research for Cancer Diagnosis & Therapy
- 4.2.3. Recommendations/Guidelines and Programs for Cancer Screening
- 4.2.4. Growing Number of Clinical Trials for Cancer Drugs
- 4.2.5. Availability of Advanced Tissue-based Companion Diagnostic Tests
- 4.2.6. Rising Global Geriatric Population
- 4.3. Restraints
- 4.3.1. Product Issues & Recalls
- 4.4. Opportunities
- 4.4.1. Rising Focus on Personalized Healthcare
- 4.4.2. Adoption of Digital Pathology & Automation in Tissue Diagnostics
- 4.4.3. Emerging Economies
- 4.5. Challenges
- 4.5.1. Shortage of Histopathologists
- 4.5.2. Low Awareness & Lack of Infrastructure in Low- & Middle-income Countries
- 4.6. The Impact of COVID-19 On the Tissue Diagnostics Market
- 5. Tissue Diagnostics Market, by Product Type
- 5.1. Introduction
- 5.2. Consumables
- 5.2.1. Kits & Reagents
- 5.2.2. Antibodies
- 5.3. Instruments
- 5.3.1. Slide Staining Systems
- 5.3.2. Tissue Microarrays
- 5.3.3. Slide Scanners
- 5.3.4. Tissue Processors
- 5.3.5. Other Instruments
- 6. Tissue Diagnostics Market, by Technique
- 6.1. Introduction
- 6.2. Immunohistochemistry (IHC)
- 6.3. In-Situ Hybridization (ISH)
- 6.4. Digital Pathology
- 6.5. H&E and Special Staining
- 6.6. Molecular Diagnostics
- 6.7. Other Techniques
- 7. Tissue Diagnostics Market, by Application
- 7.1. Introduction
- 7.2. Breast Cancer
- 7.3. Lung Cancer
- 7.4. Colorectal & Gastrointestinal Cancer
- 7.5. Prostate Cancer
- 7.6. Lymphoma
- 7.7. Other Applications
- 8. Tissue Diagnostics Market, by End User
- 8.1. Introduction
- 8.2. Hospitals & Diagnostic Laboratories
- 8.3. Research Institutes
- 8.4. Pharmaceutical Companies
- 8.5. Contract Research Organizations
- 9. Tissue Diagnostics Market, by Geography
- 9.1. Introduction
- 9.2. North America
- 9.2.1. U.S.
- 9.2.2. Canada
- 9.3. Europe
- 9.3.1. Germany
- 9.3.2. France
- 9.3.3. U.K.
- 9.3.4. Italy
- 9.3.5. Spain
- 9.3.6. Rest of Europe (RoE)
- 9.4. Asia-Pacific
- 9.4.1. China
- 9.4.2. Japan
- 9.4.3. India
- 9.4.4. Rest of Asia Pacific (RoAPAC)
- 9.5. Latin America
- 9.6. Middle East & Africa
- 10. Competitive Landscape
- 10.1. Introduction
- 10.2. Key Growth Strategies
- 10.3. Competitive Benchmarking
- 11. Company Profiles
- 11.1. F. Hoffmann-La Roche Ltd
- 11.2. Thermo Fisher Scientific Inc.
- 11.3. Abbott Laboratories
- 11.4. Danaher Corporation
- 11.5. QIAGEN N.V.
- 11.6. Becton, Dickinson and Company
- 11.7. Abcam Plc
- 11.8. Agilent Technologies, Inc.
- 11.9. Merck KGaA
- 11.10. Sakura Finetek Japan Co., Ltd.
- 11.11. Cell Signaling Technology, Inc.
- 11.12. Bio-Genex Laboratories
- 11.13. Bio SB, Inc
- 11.14. 3DHISTECH
- 11.15. Hologic, Inc.
- 12. Appendix
- 12.1. Questionnaire
- 12.2. Available Customization
List of Tables
Table 1 Global Tissue Diagnostics Market: Impact Analysis of Market Drivers (2022–2029)
Table 2 Number of New Cancer Cases, by Region, 2020 VS. 2030 (In Million)
Table 3 Common Cancer Biomarkers (Tumor/Tumor Tissue Sample)
Table 4 Cancer Screening Recommendations
Table 5 Number of Oncology Drugs in the R&D Pipeline (2016–2021)
Table 6 Recently Approved Tissue-based Companion Diagnostic Tests
Table 7 Number of New Cancer Cases in People Aged 65 Years and Over, by Region, 2020 VS. 2040 (In Million)
Table 8 Global Tissue Diagnostics Market: Impact Analysis of Market Restraints (2022–2029)
Table 9 Tissue Diagnostics Market: Product Recalls
Table 10 Patients Per Pathologist, by Country (2019)
Table 11 Global Tissue Diagnostics Market Size, by Product, 2022–2029 (USD Million)
Table 12 Global Tissue Diagnostics Consumables Market Size, by Type, 2022–2029 (USD Million)
Table 13 Global Tissue Diagnostics Consumables Market Size, by Country/Region, 2022–2029 (USD Million)
Table 14 Global Tissue Diagnostics Consumables Market Size for Kits & Reagents, by Country/Region, 2022–2029 (USD Million)
Table 15 Global Tissue Diagnostics Consumables Market Size for Antibodies, by Country/Region, 2022–2029 (USD Million)
Table 16 Global Tissue Diagnostics Instruments Market Size, by Type, 2022–2029 (USD Million)
Table 17 Global Tissue Diagnostics Instruments Market Size, by Country/Region, 2022–2029 (USD Million)
Table 18 Global Tissue Diagnostics Instruments Market Size for Slide Staining Systems, by Country/Region, 2022–2029 (USD Million)
Table 19 Global Tissue Diagnostics Instruments Market Size for Tissue Microarrays, by Country/Region, 2022–2029 (USD Million)
Table 20 Global Tissue Diagnostics Instruments Market Size for Slide Scanners, by Country/Region, 2022–2029 (USD Million)
Table 21 Global Tissue Diagnostics Instruments Market Size for Tissue Processors, by Country/Region, 2022–2029 (USD Million)
Table 22 Global Tissue Diagnostics Instruments Market Size for Other Instruments, by Country/Region, 2022–2029 (USD Million)
Table 23 Global Tissue Diagnostics Market, by Technique, 2022–2029 (USD Million)
Table 24 Global Tissue Diagnostics Market Size for Immunohistochemistry, by Country/Region, 2020–2029 (USD Million)
Table 25 Global Tissue Diagnostics Market Size For In-situ Hybridization, by Country/Region, 2022–2029 (USD Million)
Table 26 Global Tissue Diagnostics Market Size for Digital Pathology, by Country/Region, 2020–2029 (USD Million)
Table 27 Global Tissue Diagnostics Market Size for H&E and Special Staining, by Country/Region, 2020–2029 (USD Million)
Table 28 Global Tissue Diagnostics Market Size for Molecular Diagnostics, by Country/Region, 2020–2029 (USD Million)
Table 29 Global Tissue Diagnostics Market Size for Other Techniques, by Country/Region, 2020–2029 (USD Million)
Table 30 Global Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 31 U.S. Fda-Approved Companion Diagnostic Devices for Breast Cancer (Tissue)
Table 32 Global Tissue Diagnostics Market Size for Breast Cancer, by Country/ Region, 2020–2029 (USD Million)
Table 33 Common Lung Cancer Biomarkers Used in Clinical Applications
Table 34 U.S. FDA-approved Companion Diagnostic Devices for NSCLC (Tissue)
Table 35 Global Tissue Diagnostics Market Size for Lung Cancer, by Country/ Region, 2020–2029 (USD Million)
Table 36 List of Some Cleared/Approved Companion Diagnostic Devices for Colorectal Cancer Tissue
Table 37 Global Tissue Diagnostics Market Size for Colorectal & Gastrointestinal Cancer, by Country/Region, 2020–2029 (USD Million)
Table 38 Global Tissue Diagnostics Market Size for Prostate Cancer, by Country/Region, 2022–2029 (USD Million)
Table 39 Global Tissue Diagnostics Market Size for Lymphoma, by Country/Region, 2020–2029 (USD Million)
Table 40 Global Tissue Diagnostics Market Size for Other Applications, by Country/Region, 2020–2029 (USD Million)
Table 41 Global Tissue Diagnostics Market, by End User, 2020–2029 (USD Million)
Table 42 Global Tissue Diagnostics Market Size for Hospitals & Diagnostic Laboratories, by Country/Region, 2020–2029 (USD Million)
Table 43 Global Tissue Diagnostics Market Size for Research Institutes, by Country/Region, 2020–2029 (USD Million)
Table 44 Global Tissue Diagnostics Market Size for Pharmaceutical Companies, by Country/Region, 2020–2029 (USD Million)
Table 45 Global Tissue Diagnostics Market Size for Contract Research Organization, by Country/Region, 2020–2029 (USD Million)
Table 46 Global Tissue Diagnostics Market Size, by Country/Region, 2020–2029 (USD Million)
Table 47 North America: Tissue Diagnostics Market Size, by Country, 2020–2029 (USD Million)
Table 48 North America: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 49 North America: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 50 North America: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 51 North America: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 52 North America: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 53 North America: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 54 U.S.: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 55 U.S.: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 56 U.S.: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 57 U.S.: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 58 U.S.: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 59 U.S.: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 60 Canada: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 61 Canada: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 62 Canada: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 63 Canada: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 64 Canada.: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 65 Canada: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 66 Europe: Tissue Diagnostics Market Size, by Country/Region, 2020–2029 (USD Million)
Table 67 Europe: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 68 Europe: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 69 Europe: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 70 Europe: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 71 Europe: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 72 Europe: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 73 Germany: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 74 Germany: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 75 Germany: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 76 Germany: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 77 Germany: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 78 Germany: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 79 France: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 80 France: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 81 France: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 82 France: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 83 France: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 84 France: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 85 U.K.: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 86 U.K.: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 87 U.K.: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 88 U.K.: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 89 U.K.: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 90 U.K.: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 91 Italy: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 92 Italy: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 93 Italy: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 94 Italy: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 95 Italy: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 96 Italy: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 97 Spain: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 98 Spain: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 99 Spain: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 100 Spain: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 101 Spain: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 102 Spain: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 103 Estimated Number of New Cancer Cases (2020)
Table 104 Healthcare Spending in the Rest of European Countries Relative to GDP, 2019
Table 105 Rest of Europe: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 106 Rest of Europe: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 107 Rest of Europe: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 108 Rest of Europe: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 109 Rest of Europe: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 110 Rest of Europe: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 111 Asia-Pacific: Tissue Diagnostics Market Size, by Country/Region, 2020–2029 (USD Million)
Table 112 Asia-Pacific: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 113 Asia-Pacific: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 114 Asia-Pacific: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 115 Asia-Pacific: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 116 Asia-Pacific: Tissue Diagnostics Market Size, by Application, 2020–2029(USD Million)
Table 117 Asia-Pacific: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 118 China: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 119 China: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 120 China: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 121 China: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 122 China: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 123 China: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 124 Japan: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 125 Japan: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 126 Japan: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 127 Japan: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 128 Japan: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 129 Japan: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 130 India: Tissue Diagnostics Market Size, by Product Type, 2020–2029 ( USD Million)
Table 131 India: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 132 India: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 133 India: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 134 India: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 135 India: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 136 Estimated Number of New Cancer Cases in Rest of Asia-Pacific Countries: 2020–2030
Table 137 Rest of Asia-Pacific: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 138 Rest of Asia-Pacific: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 139 Rest of Asia-Pacific: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 140 Rest of Asia-Pacific: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 141 Rest of Asia-Pacific: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 142 Rest of Asia-Pacific: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 143 Latin America: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 144 Latin America: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 145 Latin America: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 146 Latin America: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 147 Latin America: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 148 Latin America: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 149 New Cancer Cases and Deaths Reported in the Middle East in 2020 and 2040
Table 150 Middle East & Africa: Tissue Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 151 Middle East & Africa: Tissue Diagnostics Consumables Market Size, by Type, 2020–2029 (USD Million)
Table 152 Middle East & Africa: Tissue Diagnostics Instruments Market Size, by Type, 2020–2029 (USD Million)
Table 153 Middle East & Africa: Tissue Diagnostics Market Size, by Technique, 2020–2029 (USD Million)
Table 154 Middle East & Africa: Tissue Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 155 Middle East & Africa: Tissue Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 156 Recent Developments, by Company (2019–2022)
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Tissue Diagnostics Market Size, by Product Type, 2022–2029 (USD Million)
Figure 8 Global Tissue Diagnostics Market Size, by Technique, 2022–2029 (USD Million)
Figure 9 Global Tissue Diagnostics Market Size, by Application, 2022–2029 (USD Million)
Figure 10 Global Tissue Diagnostics Market Size, by End User, 2022–2029 (USD Million)
Figure 11 Global Tissue Diagnostics Market, by Geography
Figure 12 Market Dynamics
Figure 13 Global Cancer Prevalence, by Type (2020)
Figure 14 Percentage of Oncology Drugs Among All Drugs in the R&D Pipeline (2015–2021)
Figure 15 Population Aged 65 Years Or Over, by Region, 2020 VS. 2030 (In Million)
Figure 16 Global Tissue Diagnostics Market Size, by Product, 2022 Vs 2029 (USD Million)
Figure 17 Global Tissue Diagnostics Market Size, by Technique, 2022 Vs 2029 (USD Million)
Figure 18 Global Tissue Diagnostics Market Size, by Application, 2022 Vs 2029 (USD Million)
Figure 19 Global Tissue Diagnostics Market, by End User, 2022 Vs 2029 (USD Million)
Figure 20 Global Tissue Diagnostics Market Size, by Region, 2022 VS 2029 (USD Million)
Figure 21 North America: Tissue Diagnostics Market Snapshot
Figure 22 U.S.: Number of New Cancer Cases (2010–2030)
Figure 23 Canada: Number of Breast Cancer Cases (2014–2030)
Figure 24 Europe: Tissue Diagnostics Market Snapshot
Figure 25 Italy: Number of Breast Cancer Cases (2020–2040)
Figure 26 Asia-Pacific: Tissue Diagnostics Market Snapshot
Figure 27 Japan: Estimated Number of People Over 65 Years of Age, 2010–2050
Figure 28 Japan: New Breast Cancer Cases 2012–2020
Figure 29 India: New Breast Cancer Cases 2012–2030
Figure 30 Mexico: Per Capita Healthcare Spending, 2017–2020 (USD)
Figure 31 Latin America: Age Standardised Cancer Incidence Rates (Asrs), Per 100,000 Population, 2020
Figure 32 Latin America: Estimated Number of Cancer Cases, 2020
Figure 33 Key Growth Strategies Adopted by Leading Players (2019–2022)
Figure 34 Tissue Diagnostics Market: Competitive Benchmarking
Figure 35 F. HOFFMAN-LA ROCHE LTD.: FINANCIAL OVERVIEW (2021)
Figure 36 Thermo Fisher Scientific Inc.: FINANCIAL OVERVIEW (2021)
Figure 37 Abbott Laboratories: FINANCIAL OVERVIEW (2021)
Figure 38 Danaher Corporation: FINANCIAL OVERVIEW (2021)
Figure 39 QIAGEN N.V.: FINANCIAL OVERVIEW (2021)
Figure 40 Becton, Dickinson And Company: FINANCIAL OVERVIEW (2021)
Figure 41 Abcam Plc: Financial Overview (2021)
Figure 42 Agilent Technologies, Inc.: Financial Overview (2021)
Figure 43 Merck KGaA: Financial Overview (2021)
Figure 44 Hologic Inc.: FINANCIAL OVERVIEW (2021)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Tissue Engineering Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Nov-2024
Rapid Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Sep-2024
North America Tissue Diagnostics Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jun-2024
Livestock Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: May-2024
Tuberculosis Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: May-2024
